Merck (MRK) Cash & Equivalents (2009 - 2026)

Merck (MRK) has 18 years of Cash & Equivalents data on file, last reported at $5.3 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $5.3 billion, down 38.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 billion (down 38.27% YoY), and the FY2025 annual result was $14.6 billion, up 9.99% from the prior year.
• Cash & Equivalents eased to $5.3 billion in Q1 2026 per MRK's latest filing, from $14.6 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $18.2 billion in Q3 2025 and troughed at $5.3 billion in Q1 2026.
• A 5-year average of $10.1 billion and a median of $9.7 billion in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 46.11% in 2023, then soared 99.72% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $12.7 billion in 2022, then sank by 46.11% to $6.8 billion in 2023, then surged by 93.57% to $13.2 billion in 2024, then grew by 9.99% to $14.6 billion in 2025, then sank by 63.43% to $5.3 billion in 2026.
• Business Quant data shows MRK's Cash & Equivalents at $5.3 billion in Q1 2026, $14.6 billion in Q4 2025, and $18.2 billion in Q3 2025.